JSPR Insider Trading Activity and SEC Form 4 Filings
JSPR insider trading summary
No open-market insider purchases or sales of Jasper Therapeutics, Inc. (JSPR) have been reported on SEC Form 4 in the past 12 months.
Latest JSPR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 22, 2025 | Svetlana Lucas | Director | Buy | $49K (20,000 @ $2.43) |
| Sep 22, 2025 | Ron Martell | President and CEO | Buy | $100K (41,000 @ $2.43) |
| Sep 22, 2025 | Judith Anne Shizuru | Director | Buy | $100K (41,000 @ $2.43) |
| Sep 22, 2025 | Thomas G Wiggans | Director | Buy | $100K (41,000 @ $2.43) |
| Dec 12, 2024 | Jeetinder Singh Mahal | Chief Operating Officer | Sell | $20K (900 @ $22.11) |
| Sep 12, 2024 | Jeetinder Singh Mahal | Chief Operating Officer | Sell | $19K (900 @ $21.23) |
| Jun 12, 2024 | Jeetinder Singh Mahal | Chief Operating Officer | Sell | $22K (900 @ $24.16) |
| Mar 12, 2024 | Jeetinder Singh Mahal | Chief Operating Officer | Sell | $24K (900 @ $26.44) |
| Feb 8, 2024 | Velan Capital Holdings LLC | Insider | Buy | $4.5M (350,000 @ $12.95) |
| Feb 8, 2024 | Avego Management LLC | Insider | Buy | $4.5M (350,000 @ $12.95) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.